Edesa Biotech, Inc. (EDSA) NASDAQ

2.59

-0.16(-5.82%)

Updated at October 03 03:01PM

Currency In USD

Edesa Biotech, Inc.

Address

100 Spy Court

Markham, ON L3R 5H6

Canada

Phone

289-800-9600

Sector

Healthcare

Industry

Biotechnology

Employees

16

First IPO Date

June 21, 2010

Key Executives

NameTitlePayYear Born
Dr. Pardeep Nijhawan FRCPC, M.D.Chief Executive Officer, Company Secretary & Director464,7281971
Dr. Michael J. Brooks M.B.A., Ph.D.President428,9871979
Mr. Peter John Weiler M.B.A, M.Sc.Chief Financial Officer01969

Description

Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.